Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# OncoLens

## Sitemaps
[XML Sitemap](https://wp.oncolens.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Advancing Commission on Cancer Lung Cancer Quality Standards](https://wp.oncolens.com/blog/advancing-coc-lung-cancer-quality-standards/): Download the PDF to see how cancer programs improve LCT measure performance through clearer documentation, stronger multidisciplinary workflows, and more reliable follow-up.
- [Streamline Your Cancer Registry: A Live Demo with OncoLens and CRStar](https://wp.oncolens.com/education/streamline-your-cancer-registry-with-oncolens-and-crstar/): Your registry program relies on two critical functions: efficient case finding and timely, accurate abstraction. But finding cases across multiple systems and extracting the data from within EMR notes and pdfs are manual, time-consuming efforts that slow your team down.
- [A New Era in Trial Matching: How a Wisconsin-Based IDN Uses Real-Time Oncology Data to Drive Enrollment](https://wp.oncolens.com/casestudy/a-new-era-in-trial-matching-real-time-oncology-data-to-drive-enrollment/): Download the full case study to see how real-time patient identification reshaped trial enrollment and delivered immediate results.
- [Precision in the Wild: Finding and Addressing the Needle in the Haystack](https://wp.oncolens.com/blog/precision-in-the-wild-finding-and-addressing-the-needle-in-the-haystack/): Download the PDF to see how AI, OCR, and oncology-specific insights are transforming rare patient targeting and ensuring therapies reach the right patients at the right time.
- [How One Cancer Center Found 14 Missed Patients with the OncoLens Registry Report](https://wp.oncolens.com/casestudy/how-one-cancer-center-found-14-missed-patients-with-the-oncolens-registry-report/): Download the full case study to see how the Registry Report redefined patient visibility, improved compliance, and scaled quality across cancer types.
- [How Real-Time Referral Data Transformed Breast Cancer Care at a Leading Academic Center](https://wp.oncolens.com/casestudy/how-real-time-referral-data-transformed-breast-cancer-care-at-a-leading-academic-center/): Download the full case study to see how actionable referral data reduced delays, improved compliance, and reshaped patient care coordination.
- [Oncology-Focused AI/LLM To Find the Right Patients for Your Clinical Trials](https://wp.oncolens.com/casestudy/oncology-focused-ai-llm-to-find-right-patients-for-your-clinical-trials/): Unlock the future of clinical trial recruitment with an AI-driven solution that identifies the right patients with unprecedented speed and precision.
- [OncoLens Analytics Enables a 350% Increase in Genetic Testing at Community Cancer Center](https://wp.oncolens.com/casestudy/oncolens-analytics-enables-a-350-increase-in-genetic-testing-at-community-cancer-center/): Learn how OncoLens Analytics enabled a rural community cancer center to achieve a 350% increase in genetic testing for breast cancer patients.
- [Results of a Quality Improvement Program To Increase Complete Lung Cancer Biomarker Testing Rates](https://wp.oncolens.com/casestudy/results-of-a-qip-to-increase-complete-lung-cancer-biomarker-testing-rates/): Discover how a cutting-edge quality improvement initiative is transforming lung cancer care by optimizing biomarker testing to deliver faster, more accurate treatment decisions.
- [Gastric Cancer: Enhanced Clinical Decision-Making Via Molecular Profiling](https://wp.oncolens.com/cme/gastric-cancer-enhanced-clinical-decision-making-via-molecular-profiling/): Through expert-led discussions, clinicians will learn how to engage multidisciplinary teams (MDTs) to enhance gastroesophageal (GE) cancer care coordination, from diagnosis to treatment. The program will emphasize the use of molecular profiling and biomarker testing to guide personalized treatment plans, focusing on actionable mutations and key biomarkers in GE cancers. Through case-based scenarios, faculty will explore how key molecular findings and patient/tumor characteristics influence treatment decisions, striving towards optimized outcomes for patients with GE cancers.
- [NSCLC: Individualizing Care Based on Patient and Tumor Characteristics](https://wp.oncolens.com/cme/nsclc-individualizing-care-based-on-patient-and-tumor-characteristics/): Through expert-led discussions, clinicians will learn how to engage multidisciplinary teams (MDTs) to enhance non-small cell lung cancer (NSCLC) care coordination, from diagnosis to treatment. The program will emphasize the use of molecular profiling and biomarker testing to guide personalized treatment plans, focusing on actionable mutations and key biomarkers in NSCLC. Through case-based scenarios, faculty will explore how key molecular findings and patient/tumor characteristics influence treatment decisions, striving toward optimized outcomes for patients with NSCLC.
- [The Lung-MAP (NCTID:03851445) Trial: Early Patient Tracking for Improved Accruals](https://wp.oncolens.com/blog/the-lung-map-trial-early-patient-tracking-for-improved-accruals/): The Lung-MAP trial also known as the Lung Cancer Master Protocol, is a precision medicine clinical trial designed for people with advanced non-small cell lung cancer (NSCLC) that has continued to grow after treatment. Enrollment in the Lung-MAP trial can provide critical access to targeted therapies for clinically appropriate patients.
- [Oncology Health Tech Startup Announces Series B Funding Round for Continued Growth of Cancer Treatment Platform and Research Network](https://wp.oncolens.com/news/oncology-health-tech-startup-announces-series-b-funding-round-for-continued-growth/): OncoLens, a leader in optimizing cancer treatment planning, announced it has raised $16 million in a Series B round co-led by BIP Capital and Cross Border Impact Ventures. Martin Ventures and SeedToB, existing investors in the company, also participated in this round.
- [OncoLens Announces Real-Time Oncology Patient Identification for Clinical Trials and Key Services](https://wp.oncolens.com/news/oncolens-announces-real-time-oncology-patient-id-for-clinical-trials-and-key-services/): OncoLens, a leader in optimizing cancer treatment planning, announced the launch of OncoLens Analytics and its advanced Patient ID solutions. The new solutions mark a significant breakthrough, enabling healthcare providers to deliver timely, precision care for cancer patients through real-time patient identification for clinical trials and key services.
- [Enhancing Guideline-Based Genetic Testing in Breast Patients with OncoLens Advanced Patient ID](https://wp.oncolens.com/casestudy/enhancing-guideline-based-genetic-testing-in-breast-patients-with-oncolens-advanced-patient-id/): Patients who should receive guideline-recommended genetic testing are often missed due to complex guidelines, discretionary referral practices, inefficient charting processes and siloed data and care teams. Consequently, patients who are candidates for precision therapeutics are overlooked and families cannot characterize patterns of heritability and risk, resulting in suboptimal treatments and strategies.
- [QIP to Increase Complete Lung Cancer Biomarker Testing Rates — ASCO 2024 Publication](https://wp.oncolens.com/casestudy/qip-to-increase-complete-lung-cancer-biomarker-testing-rates/): Results of a quality improvement program to increase complete lung cancer biomarker testing rates by focusing on system, physician, and other factors associated with adverse health outcomes.
- [OncoLens Connects Cancer Programs and Life Science Organizations to Increase Guideline Based Biomarker and Targeted Treatment Therapies](https://wp.oncolens.com/casestudy/oncolens-connects-cancer-programs-and-life-science-organizations-to-increase-guideline-based-biomarker-and-targeted-treatment-therapies/): Broad Based NGS Testing and Targeted Therapies in Multidisciplinary Care Teams (MDT)
- [Improved Broad Based NGS Testing and Discussion of Targeted Therapies in Multidisciplinary Care Teams](https://wp.oncolens.com/casestudy/improved-broad-based-ngs-testing-and-discussion-of-targeted-therapies-in-mdts/): Quality improvement project (QIP) with three cancer centers results in double digit improvement in biomarker testing and targeted therapy recommendations.
- [Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC](https://wp.oncolens.com/education/liquid-biopsy-and-concurrent-testing-strategies-for-patients-with-metastatic-nsclc/): Why Should You Watch This Webinar?
- [Surgical Optimization as Part of a Multidisciplinary Approach to 3D Cell Culture Chemosensitivity in HGG Patients (Session 5 of 6)](https://wp.oncolens.com/education/surgical-optimization-multidisciplinary-approach-to-3d-cell-culture-chemosensitivity-in-hgg-patients/): For this fifth installment of a six-webinar series, join us to hear how Dr. Ryan of the Virginia Mason Medical Center is utilizing surgical optimization as part of a multidisciplinary approach to 3D Cell Culture Chemosensitivity in HGG Patients.
- [Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team](https://wp.oncolens.com/cme/hitting-the-benchmarks-in-mcrc-a-precision-medicine-quality-initiative-for-the-care-team/): In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
- [Melanoma Oncolytic Immunotherapy: An Evolving Therapeutic Landscape](https://wp.oncolens.com/cme/melanoma-oncolytic-immunotherapy-an-evolving-therapeutic-landscape/): Treatment for patients with melanoma has been revolutionized by the integration of new immunotherapeutic strategies. Although anti–programmed cell death 1 (PD1) checkpoint inhibitors have greatly improved survival outcomes for many patients with advanced melanoma, effective treatment approaches are greatly needed in the setting of anti-PD1–failed melanoma. In this poor-prognosis patient population, emerging oncolytic virus immunotherapies may offer great promise. This program provides updates on the evolving landscape of oncolytic viruses and summarizes the rationale for their use in challenging treatment settings. Faculty review the latest clinical evidence and discuss the potential positioning of emerging oncolytic viruses within existing treatment paradigms for patients with advanced melanoma.
- [Project ECHO® Learning Series: Evolving Role of Bispecific Antibodies as Cancer Therapy](https://wp.oncolens.com/cme/project-echo-learning-series-evolving-role-of-bispecific-antibodies-as-cancer-therapy/): Bispecific antibodies, an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with bispecific antibodies, clinicians must understand the unique pharmacology and potential clinical and operational challenges of these agents. Successful administration of bispecific antibodies requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
- [Improved Management of Metastatic Colorectal Cancer (mCRC) through Real World Data Insights and Tumor Board Embedded Physician Education](https://wp.oncolens.com/casestudy/improved-management-of-mcrc-through-real-world-data-insights-and-tumor-board-embedded-physician-education/): In this case study, discover how a regional IDN, in collaboration with OncoLens and its partners, successfully improved the management of metastatic colorectal cancer (mCRC) through the use of real-world data insights and tumor board embedded physician education.
- [Combining 3D Cell Culture Chemosensitivity Results and NGS Profiles to Maximize Outcomes in Glioblastoma (Session 4 of 6)](https://wp.oncolens.com/education/combining-3d-cell-culture-chemosensitivity-results-and-ngs-profiles-to-maximize-outcomes-in-glioblastoma/): For this fourth installment of a six-webinar series, join us to hear how Dr. Odia of the Miami Cancer Institute at Baptist Health South Florida is using 3D Cell culture chemosensitivity results and NGS profiles to maximize outcomes in glioblastoma.
- [Rapid Identification of Cancer Patient Cohorts and Care Patterns With Generative AI](https://wp.oncolens.com/blog/rapid-identification-of-cancer-patient-cohorts-and-care-patterns-with-generative-ai/): Cancer care varies widely across different communities, but cancer centers struggle to reduce this disparity. One major obstacle is the lack of access to cancer-related data, such as stage, treatment, biomarker testing, and other indicators, from the unstructured EMR documents. Cancer registries may provide some data, but they are often outdated or incomplete, especially for biomarkers, later lines of therapy, and advanced treatments like clinical trials or CAR-T therapies.
- [Optimizing the Management of Newly Diagnosed Ovarian Cancer Including Maintenance (Session 3 of 3)](https://wp.oncolens.com/education/optimizing-management-of-newly-diagnosed-ovarian-cancer-including-maintenance/): Access presentation PDF here (opens in new window).
- [Disappointing Clinical Trial Accruals – The Cancer Center Perspective](https://wp.oncolens.com/blog/disappointing-clinical-trial-accruals-the-cancer-center-perspective/): Cancer centers call out these top three operational reasons behind disappointing clinical trial accrual numbers:
- [OncoLens Named to Inc. 5000 List of Fastest Growing Private Companies in America](https://wp.oncolens.com/news/oncolens-named-to-inc-5000-list-of-fastest-growing-private-companies-in-america/): OncoLens is Ranked #316 Nationwide and #38 among Health Focused Companies
- [Strategies for Enhancing Hospital Programs’ Quality Metric Tracking for Accreditation](https://wp.oncolens.com/blog/strategies-for-enhancing-hospital-programs-accreditation-quality-metric-tracking/): Cancer programs are required to comply with quality metrics established by accrediting bodies such as the Commission on Cancer (CoC), National Accreditation Program of Breast Cancer (NAPBC), National Accreditation Program of Rectal Cancer (NAPRC), and ASCO QOPI, among others. The metrics are being constantly updated as cancer related data increases. Some old standards are retired, and new metrics are added. These metrics add complexity to workflows and extend the time required for data collection and organization.
- [The Trend of Clinical Trials in the Community Setting](https://wp.oncolens.com/blog/the-trend-of-clinical-trials-in-the-community-setting/): Clinical trials play a pivotal role in bringing new, more effective cancer treatments to market, yet less than 5% of cancer patients enroll in clinical trials. This makes it difficult for pharmaceutical companies to meet the recruiting requirements to complete their clinical research and keeps potentially life-saving therapies out of reach of patients who could benefit from them. 
- [OncoLens Welcomes Cross-Border Impact Ventures Fund as Capital Partner to Fuel International Growth](https://wp.oncolens.com/news/oncolens-welcomes-cross-border-impact-ventures-fund-as-capital-partner-to-fuel-international-growth/): OncoLens, an AI/LLM oncology focused company, based in Atlanta, welcomes Cross-Border, a Canada based Impact Venture fund, as a capital investment partner.
- [Lung Cancer Screening and Identification of Lung Cancer Patients at All Stages (Session 2 of 3)](https://wp.oncolens.com/education/lung-cancer-screening-and-identification-of-lung-cancer-patients-at-all-stages/): Access presentation PDF here (opens in new window).
- [Personalizing Treatment in High Grade Glioma using 3D Ex Vivo Technology (Session 3 of 6)](https://wp.oncolens.com/education/personalizing-treatment-in-high-grade-glioma-using-3d-ex-vivo-technology/): For this third installment of a six webinar series, join us to hear how Dr. Rodriguez of the University of Arkansas is using live patient-specific tumor tissue to predict therapeutic response(s) in HGG patients before treatment initiation.
- [Expert Insights into Management of Advanced Triple Negative Breast Cancer (Session 1 of 3)](https://wp.oncolens.com/education/expert-insights-into-management-of-advanced-triple-negative-breast-cancer/): Access presentation PDF here (opens in new window).
- [Project ECHO®: Pulmonary Toxicities with Immune Checkpoint Inhibitors](https://wp.oncolens.com/cme/project-echo-pulmonary-toxicities-with-immune-checkpoint-inhibitors/): Ajay Sheshadri, MD, MSCI, Associate Professor Department of Pulmonary Medicine The University of Texas MD Anderson Cancer Center
- [OncoLens Virtual Tumor Board platform connects the best minds, therapies, and innovations in cancer care – in time to make a difference](https://wp.oncolens.com/news/oncolens-connects-best-cancer-care-minds-therapies-innovations-in-time-to-make-a-difference/): OncoLens and SARC Strategic Partnership Drives Nationwide Initiative for Enhanced Sarcoma Patient Care
- [Using Live Patient-specific Tumor Tissue to Predict Therapeutic Response(s) in HGG Patients Before Treatment Initiation (Session 2 of 6)](https://wp.oncolens.com/education/hgg-webinar-series-using-patient-specific-tumor-tissue-to-predict-tumor-response-before-treatment-initiation/): For this second installment of a six webinar series, join Dr. Mrugala of the Mayo Clinic, Arizona to hear how he is using live patient-specific tumor tissue to predict therapeutic response(s) in HGG patients before treatment initiation.
- [Project ECHO®: Dermatologic Toxicities with Immune Checkpoint Inhibitors](https://wp.oncolens.com/cme/project-echo-dermatologic-toxicities-with-immune-checkpoint-inhibitors/): Joshua Arbesman, MD Dermatology Cleveland Clinic Foundation Cleveland, OH
- [Functional Precision Oncology: Revolutionizing the Future of Cancer Care by Predicting Individual Patient Response(s) to Oncology Drugs (Session 1 of 6)](https://wp.oncolens.com/education/revolutionizing-the-future-of-cancer-care-by-predicting-individual-patient-responses-to-oncology-drugs/): For this first installment of a six webinar series, join Dr. Phillips and Dr. Litvack to hear how the experts are using live patient-specific tumor tissue to predict therapeutic response(s) in HGG patients before treatment initiation.
- [Project ECHO®: Hepatobiliary Toxicities with Immune Checkpoint Inhibitors](https://wp.oncolens.com/cme/project-echo-hepatobiliary-toxicities-with-immune-checkpoint-inhibitors/): Ryan M. Weight, DO, MSMedical DirectorThe Melanoma And Skin Cancer InstituteDenver, CO
- [Building and Engaging Affiliate Cancer Care Networks Webinar](https://wp.oncolens.com/education/building-and-engaging-affiliate-cancer-care-networks-webinar/): As we continue to address the burden of cancer in Kentucky, we rely on OncoLens for the technology. We can distribute the findings from the Kentucky Cancer Needs Assessment, widely to help our programs address disparities that may be present in their community. Our focus is on bringing care locally, supporting our affiliates to provide the most care possible within the local community, and complementing their treatment efforts where necessary. Their technology helps make that happen.
- [Project ECHO®: Neurological Toxicities with Immune Checkpoint Inhibitors](https://wp.oncolens.com/cme/project-echo-neurological-toxicities-with-immune-checkpoint-inhibitors/): Jocelyn E. Mohs, PharmD, BCOPDirector of PharmacySanford Medical CenterFargo, ND
- [OncoLens and Cancer Centers Overcome Clinical Trial Patient Recruitment Challenges](https://wp.oncolens.com/blog/oncolens-and-cancer-centers-overcome-clinical-trial-patient-recruitment-challenges/): Only 20% of patients consider the possibility of participating in a treatment clinical trial because they were unaware that this was an option.
- [Project ECHO®: Rheumatologic Toxicities with Immune Checkpoint Inhibitors](https://wp.oncolens.com/cme/project-echo-rheumatologic-toxicities-with-immune-checkpoint-inhibitors/): Casandra Calabrese, DOAssistant ProfessorRheumatologic and Immunologic DiseaseInfectious DiseaseTaussig Cancer CenterCleveland Clinic FoundationCleveland, OH
- [OncoLens Empowers Molecular Tumor Boards](https://wp.oncolens.com/blog/oncolens-empowers-mtbs/): Despite the 2016 launch—and 2022 reignition—of the National Cancer Institute’s Cancer MoonshotSM and the 2015 Precision Medicine Initiative, Molecular Tumor Boards to direct personalized cancer care still are few and far between. A few reasons drive that scarcity including the limited availability of molecular pathology specialists, time of preparation and research required for identification of appropriate therapies and the effort to bring a multi-disciplinary team together. OncoLens’ tumor board solutions bring efficiency and ease of access to providers and ultimately patients. Biomarker data is automatically integrated along with the patient’s clinical data and discussions can be easily extended to include the right experts and cases sourced across health system or practices.
- [Breaking Down Silos in Cancer Care: “Who The Health Started That?” Podcast Episode With Anju Mathew](https://wp.oncolens.com/news/breaking-down-silos-in-cancer-care/)
- [OncoLens Streamlines NAPRC Accreditation through Advanced Patient Tracking and Analytics Reporting](https://wp.oncolens.com/blog/oncolens-streamlines-naprc-accreditation-through-advanced-patient-tracking-and-analytics-reporting/): The American College of Surgeons launched its National Accreditation Program for Rectal Cancer (NAPRC) in 2018 with the goal of improving outcomes by standardizing treatment processes and focusing on multidisciplinary teamwork. The quality initiative was driven by a recognition that treatment outcomes have been highly variable, based on specialization, training and volume, and that outcomes in the United States lagged behind those in Europe.
- [ACCC and Boston University Present the Project ECHO® Eight-Part Webinar Series, Powered by OncoLens](https://wp.oncolens.com/news/accc-and-boston-university-present-the-project-echo-eight-part-webinar-series-powered-by-oncolens/): The Project ECHO® eight-part webinar series is powered by OncoLens, designed and managed by the Association of Community Cancer Centers (ACCC), accredited by Boston University Chobanian & Avedisian School of Medicine Barry M. Manuel Continuing Medical Education Office (BU_CME), and made possible by a grant from Bristol Myers Squibb (BMS).
- [Project ECHO®: Endocrine Toxicities with Immune Checkpoint Inhibitors](https://wp.oncolens.com/cme/project-echo-endocrine-toxicities-with-immune-checkpoint-inhibitors/): Jocelyn E. Mohs, PharmD, BCOPDirector of PharmacySanford Medical Center, FargoFargo, ND

## Pages
- [OncoLens Research Network Accelerates Innovation in Oncology](https://wp.oncolens.com/providers/research-network/): OncoLens Research Network: Accelerating Innovation in Oncology
The OncoLens Research Network (ORN) is a dynamic, collaborative ecosystem that empowers cancer centers with curated, revenue-generating opportunities in clinical research, real-world data (RWD) initiatives, and quality improvement programs.
By bridging providers with life science partners, ORN transforms oncology care through intelligent collaboration, precision analytics, and streamlined execution. Schedule a Demo Explore Modalities Integrated Research Modalities
ORN supports a full spectrum of research and improvement pathways. Initiative Type Description Real World Data (RWD) Aggregates structured and unstructured data to uncover trends, outcomes, and disparities in cancer care. Quality Improvement (QI) Drives compliance, standardization, and performance benchmarking across cancer programs. Industry-Sponsored Trials Connects centers with pharma and biotech partners for cutting-edge therapeutic studies. Current Strategic Initiatives
OncoLens is actively advancing several high-impact programs in partnership with leading cancer centers. Examples include: HER2-Targeted Testing & Treatment in Breast Cancer Supporting adoption of novel HER2-low testing protocols and expanding access to emerging targeted therapies. Biomarker Testing Compliance Enhancing adherence to NCCN and ASCO guidelines through automated prompts, dashboard tracking, and navigator alerts. Radioligand Therapy Trials Facilitating patient identification and trial enrollment for radioligand therapies in prostate and neuroendocrine tumors. Prostate Cancer Patient Journey Mapping Delivering AI-powered dashboards that visualize care pathways, identify delays, and optimize treatment sequencing. Schedule a Demo What Sets ORN Apart What Sets ORN Apart Curated Trial & Research Opportunities OncoLens conducts in-depth pre-feasibility analyses before presenting any opportunity, ensuring alignment with your patient population, operational capacity, and strategic goals. End-to-End Support From pre-screening and patient identification to data analytics and reporting, OncoLens acts as your business development arm—reducing administrative burden while driving clinical and financial impact. Hyper-Targeted Patient Identification Leverage AI-powered tools to find patients with rare mutations, misdiagnoses, or unmet needs—ensuring no one is missed for potentially life-saving therapies. Curated Trial & Research Opportunities OncoLens conducts in-depth pre-feasibility analyses before presenting any opportunity, ensuring alignment with your patient population, operational capacity, and strategic goals. End-to-End Support From pre-screening and patient identification to data analytics and reporting, OncoLens acts as your business development arm—reducing administrative burden while driving clinical and financial impact. Hyper-Targeted Patient Identification Leverage AI-powered tools to find patients with rare mutations, misdiagnoses, or unmet needs—ensuring no one is missed for potentially life-saving therapies. Contact Us Why Join ORN? Why Join the OncoLens Research Network?
Outcomes, revenue, efficiency, and visibility delivered. Improve patient outcomes through precision research Use RWD, guideline prompts, and targeted enrollment to match patients earlier and more accurately. Unlock new revenue streams via sponsored programs Tap industry partnerships aligned with your population, capacity, and growth strategy. Streamline trial operations with turnkey analytics Automated pre-screening, dashboards, and navigator alerts unify workflows across teams. Elevate your cancer program’s visibility and impact Showcase quality and outcomes to leadership, partners, and patients. Curious about available initiatives, or ready to accelerate your research impact?
Let’s explore how ORN can transform your oncology strategy.
Share your program goals, patient mix, and near-term priorities. We’ll map initiatives that fit and outline a path to launch. Discovery call and pre-feasibility snapshot Data requirements and timeline alignment Success metrics and reporting cadence
- [Smarter Cancer Registry Automation](https://wp.oncolens.com/providers/registry-automation/): Smarter Cancer Registry Automation with OncoLens
Transforming Data Extraction into Insightful Action
Cancer registrars and oncology data specialists face a growing challenge: extracting critical insights from increasingly complex medical records, lab reports, and pathology documents. With structured and unstructured data buried in PDFs, scanned files, and progress notes, abstraction and casefinding have become time-intensive tasks—often taking 90 minutes and 10 minutes per patient case respectively.
OncoLens changes that. Our AI-powered platform dramatically reduces the time and effort required to extract, validate, and report cancer data. By automating the identification of key clinical and registry-required elements, OncoLens empowers registry teams to focus on quality, not just quantity. Contact Us See What We Extract Efficiency that Matters
Automate the busywork. Elevate the impact. 40–75% reduction in data extraction time Streamline abstraction workflows and cut time-to-reporting by up to 25%. Casefinding in just 2–3 minutes AI-assisted search ensures no patient is missed and helps determine analytic status with precision. Customizable reports Tailored to your team’s needs, registry requirements, and cancer program goals. What OncoLens Extracts
Our platform intelligently identifies and extracts dozens of registry-critical data points, including: Category Examples Patient Info Demographics, Care Team, Reporting Facility ID Cancer Site & Histology ICD-O-3 / ICD-10 Topography & Morphology Codes, Grade, Laterality Tumor Details Size, TNM & AJCC Stage Group Pathology Path Report #, Specimen Collection Date Biomarkers Marker Results, Date of Diagnosis Treatment Dates Surgery, Systemic Therapy (Chemo, Hormones, Immunotherapy), Radiation Schedule a Demo How This Elevates Your Registry Elevate Your Registry’s Role
From data collection to decision support.
Cancer registry teams are no longer just data collectors—they’re becoming strategic insight providers. OncoLens helps you elevate your profile within cancer service lines by delivering timely, accurate, and actionable data that supports clinical decision-making, accreditation, and quality improvement.
Join the growing number of cancer programs using OncoLens to automate abstraction, accelerate casefinding, and unlock the full value of oncology data. Contact Us Schedule a Demo Ready to elevate your registry from data collection to insight?
Let’s talk about how we can support your team.
- [Accreditation Support](https://wp.oncolens.com/providers/accreditation-support/): CoC Accreditation Support
- [OncoLens Privacy Policy](https://wp.oncolens.com/privacy-policy/): Last updated: July 1, 2025
- [Solutions for Providers](https://wp.oncolens.com/providers/): Learn More
- [Customer Highlight: MaineGeneral](https://wp.oncolens.com/customer-highlight-mainegeneral/): Customer Highlight MaineGeneral Medical Center Automates for Future, Empowers Physicians, and Streamlines Operations with OncoLens Improvements include: Reduced tumor board prep time more than 90% Increased productivity with data and documents in one place Streamlined accreditation reporting “Today, physicians post their own cases and specify exactly what needs to be reviewed. Preparation time has decreased by more than 90%. Our team provides more value-added services to patients while the entire tumor board experience has improved for the team,” Wiggin said. Barbara Wiggin, Manager Radiation Oncology and Cancer Registry MaineGeneral Medical Center’s Harold Alfond Center for Cancer Care (HACCC) Read More About MaineGeneral and OncoLens
- [Solutions for Life Sciences](https://wp.oncolens.com/life-sciences/): Learn More
- [Solutions for Academic Institutions and NCI-Designated Cancer Centers](https://wp.oncolens.com/solution/academic-and-nci-cancer-centers/): Read more
- [Solutions for Community Cancer Centers](https://wp.oncolens.com/solution/community-cancer-centers/): Read more
- [Resources](https://wp.oncolens.com/resources/): Welcome to the OncoLens Blog Subscribe for updates — fresh insight delivered to your inbox once a month. Stay up to Date We care about protecting your data. Here’s our Privacy Policy. All News Releases Customer Stories Learning
- [Timely, Precise Cancer Care](https://wp.oncolens.com/): A Comprehensive Platform Driving the Delivery of Timely, Precise Cancer Care
Explore Our Solutions Providers Life Sciences Explore Our Solutions Providers Life Sciences OncoLens, an AI‑enabled digital healthcare platform, delivers workflow and analytics solutions grounded in the hidden information within unstructured clinical and lab data. 80% cancer staging extracted from clinical notes 650hrs hours saved in patient cohort analysis for trial matching 70% increase in appropriate biomarker testing 65% improvement in case prep for tumor conferences Watch this 2 minute video to see what OncoLens can do for you The OncoLens Research Network (ORN)
Members of the OncoLens Research Network access highly targeted opportunities to drive research, insight and revenue Highly curated clinical trials Highly curated clinical trials Precision medicine initiatives Precision medicine initiatives Real world data Real world data 45,000+ multi-disciplinary physicians 220+ cancer centers 50% of top 20 pharma partner with OncoLens 5M+ active patients under care Learn More for Providers Learn More for Life Sciences Ready to drive innovation and accelerate progress in oncology?
Reach out now to see how OncoLens can make a lasting impact. Publications and Case Studies Frequently Asked Questions How can AI-powered healthcare tools improve precision oncology and patient identification? OncoLens leverages AI to analyze structured and unstructured EMR data, enabling timely identification of patients eligible for advanced diagnostics, clinical trials or targeted therapies. Our platform supports precision oncology by streamlining patient ID workflows and surfacing key insights directly within provider and research team workflows. What makes clinical trial matching so difficult for cancer centers and sponsors? Clinical trial matching can be delayed by fragmented data and manual screening. OncoLens automates patient-to-trial matching by aligning trial I/E criteria with real-world EMR data. As an oncology focused platform, we go deep into understanding the nuances of cancer care including lines of therapy, indications of progression and more. This improves trial feasibility, reduces manual screening, and helps Life Science partners and cancer centers connect the right patients to the right trial at the right time. What makes OncoLens a leader in oncology workflow and tumor board solutions? Tumor board operations are often slowed by manual intake, inconsistent documentation, and redundant reporting tasks. OncoLens streamlines every step from case intake and CME tracking to accreditation reporting, cutting down administrative burden and boosting cross-team efficiency. How does OncoLens use healthcare data analytics to support real-world evidence and research? By combining clinical, pathology, and biomarker data, OncoLens delivers actionable insights into treatment patterns, care gaps, and demographic trends. Through the use of large language models tailored with our proprietary oncology knowledge models, our insights go deep, understanding lines of therapies, progression, and contextual information on the patient. Life Science teams and cancer centers use these analytics to inform trial design, evaluate performance, and drive quality improvement. What are the benefits of partnering with the OncoLens Research Network? The OncoLens Research Network connects Life Science companies with community and academic cancer centers. This partnership enables access to diverse patient populations, AI-driven patient matching, streamlined research workflows, highly curated industry trials, and revenue generating opportunities. How does OncoLens improve oncology registry automation and data capture? OncoLens integrates with leading EMRs to extract and standardize key data elements used in registry reporting. Our automation tools reduce manual abstraction, improve data quality, and support compliance with accreditation standards for cancer programs. How does OncoLens support collaboration between Life Science companies and cancer care teams? The OncoLens platform enables Life Science partners and oncology providers to coordinate on clinical trials, quality initiatives, and real-world data projects. Our white-glove support ensures transparency, alignment, and smooth execution from feasibility through closeout. How can healthcare data integration improve oncology decision-making? OncoLens aggregates structured and unstructured data from EMRs, pathology systems, and lab reports. This enables providers and Life Science teams to access a holistic view of the patient journey, identify trends, and unlock insights to guide treatment, research, and operational decisions. How can precision oncology be scaled across networks without increasing complexity? OncoLens enables scalable precision oncology by combining automated data extraction, AI-based matching, and robust analytics across multiple cancer centers. Whether for targeted therapies, biomarker tracking, or real-world evidence generation, OncoLens helps both providers and sponsors execute with confidence.
- [Schedule A Demo](https://wp.oncolens.com/schedule-a-demo/): Schedule a Demo Ready to drive innovation and accelerate progress in oncology?
Schedule a demo now to see how OncoLens can make a lasting impact.
- [Contact Us](https://wp.oncolens.com/contact-us/): Contact Us Contact Support support@oncolens.com Contact Sales info@oncolens.com Ready to drive innovation and accelerate progress in oncology?
Reach out now to see how OncoLens can make a lasting impact. Visit Our Headquarters ATDC
75 5th Street NW
Atlanta, GA 30308 Our headquarters is in the heart of downtown Atlanta at the world-famous Atlanta Technology Development Center (ATDC). Centered on the Georgia Tech university campus, our vibrant community of seasoned professionals along with young, aspiring engineers looking to make an impact on society creates an ideal environment for technology innovation and growth.
- [Meet Our Team](https://wp.oncolens.com/team/): Meet Our Leadership Team Trusted by leading cancer centers nationwide.
Here is a sample of our great customers.
Are you ready for your business to take off?
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa commodo. Contact Us
- [About Us](https://wp.oncolens.com/about-us/): READ MORE
- [Awards](https://wp.oncolens.com/awards/): OncoLens’ breakthrough platform has earned the company recognition throughout the clinical and technology professional communities that we serve. We’re proud to see the hard work and dedication of our team acknowledged by our customers and peers.

## Team Members

## Careers
- [Senior Data Engineer](https://wp.oncolens.com/careers/data-engineer/): It is hard to find someone in today’s world who hasn’t been impacted by cancer. At OncoLens, we envision a world where every cancer patient has access to the best possible minds, therapies, and innovations in care—in time to make a difference. We deliver tech-based solutions for cancer care professionals and life science companies to improve treatment plans and save lives.

## Categories
- [Blog](https://wp.oncolens.com/blog/)
- [Case Studies](https://wp.oncolens.com/casestudy/)
- [CME](https://wp.oncolens.com/cme/)
- [Education](https://wp.oncolens.com/education/)
- [News and Events](https://wp.oncolens.com/news/)